Apparatus and methods calculate and deliver doses of insulin and optionally glucagon into a subject. online operation controls delivery of correction doses of insulin automatically in response to regular glucose measurements from a sensor, and offline operation calculates and delivers correction doses based on isolated glucose measurements and information gathered autonomously during preceding online operation. In another aspect, offline operation includes automatically calculating and administering meal doses based on information gathered autonomously during preceding periods of online operation. Both methods include generating relevant control parameters tailored to the individual and continually converged upon and potentially modulated during online operation. The control parameters are employed in real time during periods of offline operation to regulate glucose level without the need for user-provided control parameters such as correction factors and insulin-to-carbohydrate ratios.
|
10. A method of operating a controller for a glucose level control system having a glucose sensor and an insulin delivery device, the glucose sensor being operative to continually measure a glucose level of a subject and generate a corresponding glucose level signal, the insulin delivery device being operative in response to an insulin dose control signal to infuse insulin into the subject, comprising:
performing online operation employing a control algorithm including (i) regular administration of correction doses of insulin based on control parameters of the control algorithm and regular periodic sampling of glucose levels via the glucose sensor, and (ii) autonomously adjusting the control parameters to tailor the control parameters to the subject; and
performing offline operation including (iii) evolving a state of the control algorithm over time without sampling of glucose levels and without automatic administration of the correction doses of insulin, and (iv) correction dosing operations each including administration of a correction dose of insulin in response to an isolated glucose measurement provided to the controller, the correction dose being calculated by the controller based on the isolated glucose measurement, the control parameters, and the state of the control algorithm as evolved at the time of the correction dosing operation.
19. A glucose level control system, comprising:
a glucose sensor operative to continually measure glucose level of a subject and generate a corresponding glucose level signal;
an insulin delivery device operative in response to an insulin dose control signal to infuse insulin into the subject; and
a controller having online operation and offline operation to generate the insulin dose control signal to achieve and maintain euglycemia in the subject, online operation employing a control algorithm including (i) administration of meal doses of insulin in response to a meal dose control input and automatically calculated by the controller based on preceding meal doses and corresponding prandial and post-prandial responses of the subject as reflected in sampling of glucose levels via the glucose sensor and (ii) autonomously adjusting control parameters used to determine meal dose size to tailor the control parameters to the subject, offline operation including (iii) evolving a state of the control algorithm over time without sampling of glucose levels, and (iv) meal dosing operations each including administration of a meal dose of insulin in response to the meal dose control input and calculated by the controller based on an isolated glucose measurement, the control parameters, and a state of the control algorithm as evolved at the time of the meal dosing operation.
1. A glucose level control system, comprising:
a glucose sensor operative to continually measure a glucose level of a subject and generate a corresponding glucose level signal;
an insulin delivery device operative in response to an insulin dose control signal to infuse insulin into the subject; and
a controller having online operation and offline operation to generate the insulin dose control signal to achieve and maintain euglycemia in the subject, online operation employing a control algorithm including (i) regular administration of correction doses of insulin based on control parameters of the control algorithm and regular periodic sampling of glucose levels via the glucose sensor, and (ii) autonomously adjusting the control parameters to tailor the control parameters to the subject, offline operation including (iii) evolving a state of the control algorithm over time without sampling of glucose levels and without automatic administration of the correction doses of insulin, and (iv) correction dosing operations each including administration of a correction dose of insulin in response to an isolated glucose measurement provided to the controller, the correction dose being calculated by the controller based on the isolated glucose measurement, the control parameters, and a state of the control algorithm as evolved at the time of the correction dosing operation.
0. 30. A method of operating a controller in a glucose level control system having a glucose sensor and an insulin delivery device, the controller having respective interfaces to the insulin delivery device and the glucose sensor (1) to convey an insulin dose control signal to the insulin delivery device for controlling infusion of insulin into a subject, and (2) to receive a glucose level signal from the glucose sensor indicating a glucose level of the subject, the method comprising:
performing online operation employing a control algorithm including (i) regularly administering correction doses of insulin based on control parameters of the control algorithm and regular periodic sampling of glucose levels of the subject via the glucose sensor, and (ii) autonomously adjusting the control parameters to tailor the control parameters to the subject; and
performing offline operation including (iii) evolving a state of the control algorithm over time without sampling of glucose levels and without automatic administration of the correction doses of insulin, and (iv) correction dosing operations each including administration of a correction dose of insulin in response to an isolated glucose measurement provided to the controller, the correction dose being calculated by the controller based on (i) the isolated glucose measurement, (ii) the control parameters, and (iii) the state of the control algorithm as evolved at the time of the correction dosing operation.
0. 39. A controller for use in a glucose level control system having an insulin delivery device and a glucose sensor, the controller comprising:
processing circuitry including one or more processors;
memory; and
input/output circuitry,
the input/output circuitry providing respective interfaces to the insulin delivery device and the glucose sensor (1) to convey an insulin dose control signal to the insulin delivery device for controlling infusion of insulin into a subject, and (2) to receive a glucose level signal from the glucose sensor indicating a glucose level of the subject,
the memory storing computer program instructions executed by the processors to provide online operation and offline operation of the glucose level control system to generate the insulin dose control signal to achieve and maintain euglycemia in the subject, online operation employing a control algorithm including (i) administration of meal doses of insulin in response to a meal dose control input and automatically calculated by the controller based on preceding meal doses and corresponding prandial and post-prandial responses of the subject as reflected in sampling of glucose levels via the glucose sensor and (ii) autonomously adjusting control parameters used to determine meal dose size to tailor the control parameters to the subject, offline operation including (iii) evolving a state of the control algorithm over time without sampling of glucose levels, and (iv) meal dosing operations each including administration of a meal dose of insulin in response to the meal dose control input and calculated by the controller based on the control parameters and the state of the control algorithm as evolved at the time of the meal dosing operation.
0. 21. A controller for use in a glucose level control system having an insulin delivery device and a glucose sensor, the controller comprising:
processing circuitry including one or more processors;
memory; and
input/output circuitry,
the input/output circuitry providing respective interfaces to the insulin delivery device and the glucose sensor (1) to convey an insulin dose control signal to the insulin delivery device for controlling infusion of insulin into a subject, and (2) to receive a glucose level signal from the glucose sensor indicating a glucose level of the subject,
the memory storing computer program instructions executed by the processors to provide online operation and offline operation of the glucose level control system to generate the insulin dose control signal to achieve and maintain euglycemia in the subject, the online operation employing a control algorithm including (i) regular administration of correction doses of insulin based on control parameters of the control algorithm and regular periodic sampling of glucose levels via the glucose sensor, and (ii) autonomously adjusting the control parameters to tailor the control parameters to the subject, offline operation including (iii) evolving a state of the control algorithm over time without sampling of glucose levels and without automatic administration of the correction doses of insulin, and (iv) correction dosing operations each including administration of a correction dose of insulin in response to an isolated glucose measurement provided to the controller, the correction dose being calculated by the controller based on (i) the isolated glucose measurement, (ii) the control parameters, and (iii) the state of the control algorithm as evolved at the time of the correction dosing operation.
2. A glucose level control system according to
3. A glucose level control system according to
4. A glucose level control system according to
5. A glucose level control system according to
6. A glucose level control system according to
7. A glucose level control system according to
8. A glucose level control system according to
9. A glucose level control system according to
11. A method according to
12. A method according to
13. A method according to
14. A method according to
15. A method according to
16. A method according to
17. A method according to
18. A method according to
20. A glucose level control system according to
0. 22. The controller of
0. 23. The controller of
0. 24. The controller of
0. 25. The controller of
0. 26. The controller of
0. 27. The controller of
0. 28. The controller of
0. 29. The controller of
0. 31. The method of
0. 32. The method of
0. 33. The method of
0. 34. The method of
0. 35. The method of
0. 36. The method of
0. 37. The method of
0. 38. The method of
0. 40. The controller of
|
The invention was made with Government support under Contract No. DK085633 awarded by the National Institutes of Health. The Government has certain rights in the invention.
Standard-of-care insulin therapies for regulating blood glucose in diabetes typically involve either multiple daily subcutaneous injections or subcutaneous infusion with an insulin pump. Typically, combinations of basal and bolus insulin are administered to meet the subject's basal metabolic insulin requirement; correction bolus doses are administered to regulate hyperglycemia; and additional meal bolus doses are added to provide insulin for food consumption. In current usual care, a correction bolus of insulin that is typically administered to treat a hyperglycemic state is based on an estimate of the individual's so-called “correction factor(s)”, which relate how much insulin is estimated by the user to adequately compensate for different levels of hyperglycemia. Correction factors are heuristically estimated on an individual basis and are modified (essentially by trial-and-error) from time to time. This is similar to how basal rates of insulin are heuristically estimated on an individual basis to provide basal metabolic insulin requirements.
Similarly, meal bolus insulin doses taken around food consumption are also typically estimated heuristically on an individual basis based on the quantity and content (carbohydrate and other) of the food, in conjunction with a heuristic estimate of the individual's so-called “insulin-to-carbohydrate ratio(s)”, among other factors such as the time of the day, physical activity, health state, emotional state, etc. The right correction bolus doses, insulin basal rates, and meal bolus doses alike, are all essentially determined by trial-and-error experience and could vary significantly among individuals as well as for an individual over time; yet, they are all critical determinants of how well an individual is able to control their blood glucose. Dosing requirements are also subject to factors such as the time of the day, physical activity, health state, emotional state, etc., and could vary over periods of hours, days, or weeks due to transient changes (e.g. due to circadian hormonal fluctuations, current illness, physical activity, or emotional state) and/or periods of months or years due to developmental changes (e.g. due to hormonal changes that occur during puberty or menopause).
Disclosed herein are automated methods for calculating and delivering doses of insulin or insulin-like agents and/or a counter-regulatory agent such as glucagon or glucagon-like agents, infused into a subject via any of several routes including subcutaneously, intramuscularly, intraperitoneally, or intravenously. The methods adapt to an individual user and do not require inputs such as “correction factors” and “insulin-to-carbohydrate” factors.
A first disclosed method includes periods of online operation when a controller is operating to control the delivery of correction boluses of insulin automatically in response to regular glucose levels provided by a sensor at regular intervals (e.g., on the order of 1-15 minutes apart), also referred to as “sampling intervals”. Online operation of the controller refers to sampling intervals when there are a glucose measurements provided by the sensor and offline operation refers to sampling intervals when there are no glucose measurements provided by the sensor. The method further includes offline operation when a controller responds automatically to isolated glucose measurements (e.g., provided by the subject to the controller), using information that was gathered autonomously by the control system during preceding periods of online operation. A second disclosed method includes automatically calculating and administering meal bolus doses in response to meal announcements during periods of offline operation based on information that was gathered autonomously by the control system during preceding periods of online operation. The two methods involve autonomously generating relevant control parameters that are tailored to the individual and are continually converged upon and potentially modulated during periods of online operation. The control parameters are then employed in real time during periods of offline operation in order to regulate glucose levels without the need for the user to provide corresponding control parameters (e.g. insulin-to-carbohydrate ratios, or insulin correction factors). The methods may be used independently or together, and they may also be supplemented by analogous control methods for delivery of a counter-regulatory agent during offline operation, as described more below.
The foregoing and other objects, features and advantages will be apparent from the following description of particular embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views.
The disclosures of the following published patent documents are incorporated by reference herein:
US patent publication 2008/0208113 A1
PCT application publication WO 2012/058694 A2
US patent application publication 20130245547 A1
For online or autonomous operation, a glucose sensor 16 is operatively coupled to the subject 12 to continually sample a glucose level of the subject 12. Sensing may be accomplished in a variety of ways, generally involving some form of physical coupling 21 between the subject 12 and the glucose sensor 16. A controller 18 controls operation of the delivery device(s) 14 as a function of a glucose level signal 19 from the glucose sensor 16 and subject to programmed input parameters (PARAMS) 20 which may be provided by a user such as the subject 12. One input parameter for automatic operation is the weight of the subject 12. One feature of the disclosed technique is its ability to provide effective automated control without receiving explicit information regarding either meals that the subject 12 has ingested or any other “feedforward” information, which is achieved in part by an adaptive aspect to operation of the controller 18.
The controller 18 is an electrical device with control circuitry that provides operating functionality as described herein. In one embodiment, the controller 18 may be realized as a computerized device having computer instruction processing circuitry that executes one or more computer programs each including respective sets of computer instructions. In this case the processing circuitry will generally include one or more processors along with memory and input/output circuitry coupled to the processor(s), where the memory stores computer program instructions and data and the input/output circuitry provides interface(s) to external devices such as the glucose sensor 16 and delivery device(s) 14.
The control system 10 is also able to operate in an offline manner in which it is used to provide delivery of insulin (and potentially glucagon as well) but not based on glucose levels reported by the sensor 16. Thus, overall operation may be divided between online periods each including a succession of sampling intervals when a glucose signal (level) 19 is available, and offline periods each including a succession of sampling intervals when the glucose signal (level) 19 is either completely or only intermittently unavailable. The description below uses the terms “online” and “offline” for these periods. Also, offline operation may be user-selected for some reason even when a glucose level signal 19 is available for use.
User control inputs (USER CNTLs 23) may be provided via a local or remote user interface of some type. In one embodiment, the user interface may resemble that of conventional insulin pumps or similar devices, e.g., by including control buttons for commanding the delivery of a bolus and perhaps a small display. In other embodiments, the system may have a wired or wireless interface to a remote device that may incorporate a fuller-function user interface, such as a smartphone or analogous personal computing device. In offline mode, the glucose sensor 16 may be absent, non-functioning, or not coupled to the subject 12, with the result that the blood glucose signal 19 is not available to control automatic operation.
The description herein refers to a “user” as the source of the user control inputs 23. In one typical use, the glucose level control system 10 is a personal device worn by a subject 12 for continual glucose control. In this case the user and subject 12 are the same person. In other uses, there may be another person involved in the care of the subject 12 and providing control input, and in such a case that other person has the role of user.
Also shown in
The controllers 22-28 may be operated in either the online/automatic mode or in the offline mode. In the automated mode, the corrective controller 26 regulates glucose level using a control scheme such as described in US patent publication 2008/0208113A1, the contents of which are incorporated by reference herein. The basal controller 24 and priming insulin controller 28 may perform adaptive automated control as described in international patent application publication WO 2012/058694 A2, the contents of which are incorporated by reference herein. The controllers 22-28 generally employ control methods or algorithms that include control parameters that are mathematically combined with reported glucose values to generate an output value that is converted (either directly or via additional conditioning) into the dose control signals 34, 42. For example, the control scheme described in US patent publication 2008/0208113A1 includes a generalized predictive control (GPC) method that incorporates a variety of control parameters. The control algorithms are generally adaptive, meaning that control parameters are dynamically adjusted during operation to reflect changing operating circumstances and a “learning” aspect—by monitoring its own operation, the algorithm adjusts its operation to be more specifically tailored to the individual user, enhancing the algorithm's effectiveness and reducing or avoiding a need for additional explicit input information about the user. It should be noted that the input parameters 20 form part of the control parameters used by the control algorithm; other control parameters are internal parameters according to the specifics of the algorithm, and selected ones of those internal control parameters are dynamically adjusted to realize the adaptation of the control algorithm.
One feature of operation is the ability of the controllers to learn from recent past periods of online operation and to use that learning during offline operation. Specifically, described below are two methods that are usable independently or together in offline operation. A first method automatically calculates the correct size of a correction bolus of insulin at a time of receiving an isolated glucose measurement, the correction bolus then being administered by the system in response to a user control input. A second method automatically calculates the correct size of a meal bolus of insulin and administers it in response to a user control input. Both methods utilize information obtained during past periods of online operation to automatically calculate correct values, freeing the user of a need to make the calculation or provide a correction factor.
I. Automatically Calculated Correction Bolus During Periods of Offline Operation
The method for automatically calculating a correction bolus dose in real time during offline operation is achieved by invoking an online control algorithm individually on isolated glucose measurements as they are provided to the control system 10 during offline operation. These isolated glucose measurements may be blood glucose (BG) measurements from a glucose meter of any kind or glucose measurements obtained from another glucose monitor of any kind, provided to the control system 10 via the user controls 23. The automatic calculation of the correction bolus doses follows the same method described for continuous online control in the above-referenced US patent publication 2008/0208113A1, treating each isolated glucose measurement provided during offline operation as if it were a glucose value obtained from the glucose level signal 19. Effectively, each correction bolus operation is a brief resumption of online control. Time gaps in glucose data are taken into account by the online algorithm in its calculations of the effective rate of change of glucose as well as the overall outstanding insulin accumulation when the online algorithm is invoked in real time around the isolated glucose measurements. In particular, during offline operation the algorithm continues to mark the passage of time as a succession of sampling intervals in which it does not receive glucose sensor input and it does not generate regular correction doses of insulin. It continues to model the diminishing of on-board insulin level in the subject 12 over time, so that at any given time it has an accurate estimate of the future effect of previously administered insulin. When the controller 18 receives an isolated glucose measurement from the user along with an instruction to generate a correction dose, the algorithm performs an interpolation between the current glucose measurement and the most recent glucose sample value (from a preceding period of online control or isolated glucose measurement) to obtain estimated glucose values for recent sampling intervals as needed for the algorithm's computations.
In one embodiment the system may request user confirmation before delivering the automatically calculated correction bolus, while in other embodiments it may not request confirmation or there may be a configuration setting to control whether confirmation is requested. Similarly, the system may or may not disclose the dosing amount to the user, and/or may allow the user to modify the dosing amount (these behaviors also being configurable in one embodiment).
At 52, the controller 18 engages in offline operation that includes (iii) evolving a state of the control algorithm over time without sampling of glucose levels and without automatic administration of the correction doses of insulin, and (iv) correction bolus operations each including administering a correction bolus of that is calculated by the controller based on the isolated glucose measurement, the control parameters, and a state of the control algorithm as evolved at the time of the correction bolus operation. In this description, the term “correction bolus operation” is used for convenience; this operation may alternatively be referred to using the more general term “correction dosing operation.”
The correction bolus may be calculated by the controller 18 during offline operation assuming a first target glucose level or range higher than a second target glucose level or range assumed during online operation. Additionally, the correction dose of insulin may be calculated by the controller 18 during periods when the counter-regulatory delivery channel or device 14-1 is unavailable, and assuming a first target glucose level or range higher than a second target glucose level or range assumed when the counter-regulatory delivery channel or device is available.
Additional details of the method for automatically calculating a correction bolus dose during offline operation and its effects are now provided with reference to data generated by simulations of operation based on assumed characteristics of a subject or user.
During online periods in the simulation of
II. Automatically Calculated Meal Bolus Dose During Periods of Offline Control
A method is also described for automatically calculating a meal bolus dose in real time during offline operation by an online control algorithm based on the prandial and post-prandial response(s) during preceding period(s) of online operation when a meal bolus was administered for a meal or snack of the corresponding kind and/or time interval of day (breakfast, lunch, or dinner). The automatic calculation from preceding period(s) of online operation could include multiple incidents of each kind of meal bolus dose (e.g. multiple days having occasions of breakfast, lunch, or dinner). The automatic calculation of the meal bolus doses during offline operation may follow the same method described in the above-referenced international patent application publication WO 2012/058694 A2 for its implementation during online operation, i.e. meal bolus doses are adapted based on online operation and in this case are issued in the same way during offline operation as they are during continual online operation.
At 62, offline operation includes (iii) evolving a state of the control algorithm over time without sampling of glucose levels, and (iv) meal bolus operations each including administration of a meal bolus of insulin in response to the meal bolus control input and calculated by the controller based on the isolated glucose measurement, the control parameters, and a state of the control algorithm as evolved at the time of the meal bolus operation. The meal bolus may be administered in one continuous ejection or discharge from the insulin pump, or it may be administered as multiple ejections over a short period (e.g., split over consecutive sampling intervals). Some pumps enforce a limit for a single ejection, so if the bolus to be delivered exceeds that limit then it may be delivered using multiple ejections over a short period (e.g., split over consecutive sampling intervals). In this description, the term “meal bolus operation” is used for convenience; this operation may alternatively be referred to using the more general term “meal dosing operation.”
More specifically,
Note that the user may choose not to utilize the meal bolus dose option when in online operation, as the control algorithm is able to automatically respond to prandial or post-prandial glucose excursions when in online operation. However, such an automatic online response will be absent or ineffective if the prandial or post-prandial period occurs when in offline operation. Therefore, good glycemic control generally requires using the meal bolus dose option around the times of food consumption during offline operation. Since the meal bolus dose is effectively adapted during online operation, it follows that in order to get optimal control when using it during offline operation, the user should occasionally, if not regularly, use the meal bolus dose option in online operation. Occasional utilization could be on the order of once per week for a couple of weeks for each kind and/or time interval of day (breakfast, lunch, or dinner), but could also be more or less frequent than that, and/or altogether on an irregular time basis. Such occasional online usage over time allows for repeated adaptations of the meal bolus dose, which essentially updates the meal bolus dose magnitude(s) to better suit the user's needs based on their own determinations of the relative size of meals. In summary, while the meal bolus dose option may or may not be necessary for effective control under online operation, using it (at least occasionally) during online operation allows adapting the meal bolus dose magnitude(s) so as to be more effective when used in offline operation.
Superposition of the Two Methods
Other Control Aspects
Independently, the control system 10 can, in a similar manner, automatically calculate in real time a correction bolus dose of a counter-regulatory agent (such as glucagon) during online operation. With a counter-regulatory agent being available for use by the control system 10, offline operation action around an isolated glucose measurement could include real-time doses of the counter-regulatory agent. The system can still issue a correction bolus of insulin in an independent manner, so that it can exercise both correction bolus kinds (insulin and glucagon) or one kind without the other.
In both the online and offline operations, the control algorithm may allow the subject to issue a microburst or rescue dose of counter-regulatory agent, with a value of the microburst or rescue dose being calculated by the controller 18.
All of the methods described above could be used in the in-patient (e.g. critical care units or general wards, where the route of drug administration could vary and where dextrose is an example of a counter-regulatory agent) or out-patient settings and could be used in the context of an autonomous or semi-autonomous online glucose control system 10 (e.g. sensor-augmented infusion system). The methods could also be applied in online operation separately or in conjunction in various combinations. When employed in online operation, these methods could ultimately render obsolete notions of requiring the user (or care provider) to know and set control parameters such as insulin-to-carbohydrate ratios, correction factors (for both insulin or insulin-like agent and a counter-regulatory agent), as well as basal rates of insulin infusion.
While various embodiments of the invention have been particularly shown and described, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
Damiano, Edward R., El-Khatib, Firas H.
Patent | Priority | Assignee | Title |
Patent | Priority | Assignee | Title |
10188793, | Jun 10 2014 | INSULET CORPORATION | Insulin on board calculation, schedule and delivery |
10188795, | Oct 31 2010 | Trustees of Boston University; The General Hospital Corporation | Blood glucose control system |
10357607, | May 24 2007 | Tandem Diabetes Care, Inc. | Correction factor testing using frequent blood glucose input |
10463786, | Mar 15 2013 | Tandem Diabetes Care, Inc. | Method and device utilizing insulin delivery protocols |
10543313, | Jan 31 2014 | Trustees of Boston University | Glucose level control system with offline control based on preceding periods of online control |
10569016, | Dec 29 2015 | TANDEM DIABETES CARE, INC | System and method for switching between closed loop and open loop control of an ambulatory infusion pump |
10653834, | Jun 07 2012 | Tandem Diabetes Care, Inc. | Device and method for training users of ambulatory medical devices |
4280494, | Jun 26 1979 | System for automatic feedback-controlled administration of drugs | |
4464170, | Sep 29 1982 | Miles Laboratories, Inc. | Blood glucose control apparatus and method |
5665065, | May 26 1995 | MEDTRONIC MINIMED, INC | Medication infusion device with blood glucose data input |
6544212, | Jul 31 2001 | Roche Diabetes Care, Inc | Diabetes management system |
6554798, | Aug 18 1998 | MEDTRONIC MINIMED, INC | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
6572542, | Mar 03 2000 | Medtronic, Inc. | System and method for monitoring and controlling the glycemic state of a patient |
7347836, | Sep 09 1992 | SMITHS MEDICAL ASD, INC | Drug pump systems and methods |
7491187, | Mar 22 2002 | K U LEUVEN RESEARCH & DEVELOPMENT | Automatic infusion system based on an adaptive patient model |
7651845, | May 13 2004 | The Regents of the University of California | Method and apparatus for glucose control and insulin dosing for diabetics |
7655618, | Dec 27 2002 | HOWL TECHNOLOGIES, INC | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
7678762, | Dec 27 2002 | ENJECT, INC | Methods for reducing the risk of hypoglycemia |
7678763, | Dec 27 2002 | DiObex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
7683027, | Dec 27 2002 | ENJECT, INC | Methods relating to hypoglycemic unawareness |
7766829, | Nov 04 2005 | ABBOTT DIABETES CARE, INC | Method and system for providing basal profile modification in analyte monitoring and management systems |
7806854, | May 13 2005 | Trustees of Boston University; The Board of Trustees of the University of Illinois | Fully automated control system for type 1 diabetes |
7850641, | Sep 07 2001 | Medtronic MiniMed, Inc. | Safety limits for closed-loop infusion pump control |
8185412, | Mar 28 2008 | Method and apparatus for chronic care treatment control with custom named-type factors and user estimation error correction | |
8273052, | May 13 2005 | Trustees of Boston University | Fully automated control system for type 1 diabetes |
8348842, | May 14 2004 | Flint Hills Scientific, L.L.C. | Method and system for implantable glucose monitoring and control of a glycemic state of a subject |
8377031, | Oct 23 2007 | ABBOTT DIABETES CARE, INC | Closed loop control system with safety parameters and methods |
8454510, | Jun 20 2007 | Roche Diabetes Care, Inc | Method and device for assessing carbohydrate-to-insulin ratio |
8457901, | Apr 04 2008 | Hygieia, Inc. | System for optimizing a patient's insulin dosage regimen |
8478557, | Jul 31 2009 | Abbott Diabetes Care Inc | Method and apparatus for providing analyte monitoring system calibration accuracy |
8562587, | Feb 25 2009 | University of Virginia Patent Foundation | CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction of insulin delivery |
8622988, | Aug 31 2008 | ABBOTT DIABETES CARE, INC | Variable rate closed loop control and methods |
8679016, | Dec 29 2006 | Medtronic MiniMed, Inc. | Method and system for providing sensor redundancy |
8690820, | Oct 06 2009 | Illinois Institute of Technology | Automatic insulin pumps using recursive multivariable models and adaptive control algorithms |
8840582, | Jan 09 2008 | TANDEM DIABETES CARE, INC | Infusion pump with activity monitoring |
9283323, | Aug 12 2011 | GENE ONYX LIMITED | Insulin pump |
9351670, | Dec 31 2012 | Abbott Diabetes Care Inc | Glycemic risk determination based on variability of glucose levels |
9398869, | Mar 26 2010 | University of Virginia Patent Foundation | Method, system, and computer program product for improving the accuracy of glucose sensors using insulin delivery observation in diabetes |
9445757, | Dec 29 2010 | Medtronic MiniMed, Inc. | Glycemic health metric determination and application |
9486578, | Dec 07 2012 | JDRF INTERNATIONAL | Method and system for tuning a closed-loop controller for an artificial pancreas |
9750438, | Feb 25 2009 | University of Virginia Patent Foundation | CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction of insulin delivery |
9833570, | Apr 25 2013 | The General Hospital Corporation | Blood glucose control system |
9839395, | Dec 17 2007 | DEXCOM, INC | Systems and methods for processing sensor data |
9901677, | Oct 16 2012 | INSULET CORPORATION | Infusion pump system and methods |
9907909, | Dec 20 2012 | JDRF INTERNATIONAL | Method and system for a hybrid control-to-target and control-to-range model predictive control of an artificial pancreas |
9999728, | Aug 30 2012 | Medtronic MiniMed, Inc. | Regulating entry into a closed-loop operating mode of an insulin infusion system |
20030181852, | |||
20040028707, | |||
20040034295, | |||
20040147872, | |||
20040253736, | |||
20050272640, | |||
20060272652, | |||
20060276771, | |||
20070282299, | |||
20080154187, | |||
20080183060, | |||
20080208113, | |||
20080269714, | |||
20080319384, | |||
20090006061, | |||
20090164239, | |||
20090177154, | |||
20100057057, | |||
20100082167, | |||
20100125241, | |||
20100137788, | |||
20100145262, | |||
20100256466, | |||
20100262117, | |||
20100292634, | |||
20110021898, | |||
20110054391, | |||
20110106049, | |||
20110208155, | |||
20110208156, | |||
20120065894, | |||
20120078067, | |||
20120245556, | |||
20120246106, | |||
20120265126, | |||
20120265722, | |||
20120277723, | |||
20120283694, | |||
20130190583, | |||
20140031786, | |||
20150018633, | |||
20150217052, | |||
20150217053, | |||
20160224756, | |||
20160331898, | |||
20170095612, | |||
20170203038, | |||
20180185587, | |||
20180200440, | |||
20190214124, | |||
20190247578, | |||
20190336684, | |||
20200254240, | |||
CA2365316, | |||
CN101795623, | |||
CN101821741, | |||
CN102077108, | |||
CN102667787, | |||
CN102802522, | |||
CN102812121, | |||
CN102946923, | |||
CN104667368, | |||
CN104667379, | |||
CN1973768, | |||
CN201186082, | |||
EP1575656, | |||
EP1860583, | |||
EP3453414, | |||
JP2001204817, | |||
JP2003079723, | |||
JP2004502474, | |||
JP2007312923, | |||
JP2007529241, | |||
JP2012516735, | |||
JP2012519018, | |||
JP3500129, | |||
WO2012058694, | |||
WO2012108938, | |||
WO4006982, | |||
WO4084820, | |||
WO6124716, | |||
WO8057384, | |||
WO8094249, | |||
WO8114254, | |||
WO8157780, | |||
WO9001349, | |||
WO12058694, | |||
WO14110541, | |||
WO15021041, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Dec 07 2015 | DAMIANO, EDWARD R | Trustees of Boston University | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 056913 | /0152 | |
Dec 07 2015 | EL-KHATIB, FIRAS H | Trustees of Boston University | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 056913 | /0152 | |
May 06 2021 | Trustees of Boston University | (assignment on the face of the patent) | / |
Date | Maintenance Fee Events |
May 06 2021 | BIG: Entity status set to Undiscounted (note the period is included in the code). |
May 10 2021 | SMAL: Entity status set to Small. |
Date | Maintenance Schedule |
Aug 13 2027 | 4 years fee payment window open |
Feb 13 2028 | 6 months grace period start (w surcharge) |
Aug 13 2028 | patent expiry (for year 4) |
Aug 13 2030 | 2 years to revive unintentionally abandoned end. (for year 4) |
Aug 13 2031 | 8 years fee payment window open |
Feb 13 2032 | 6 months grace period start (w surcharge) |
Aug 13 2032 | patent expiry (for year 8) |
Aug 13 2034 | 2 years to revive unintentionally abandoned end. (for year 8) |
Aug 13 2035 | 12 years fee payment window open |
Feb 13 2036 | 6 months grace period start (w surcharge) |
Aug 13 2036 | patent expiry (for year 12) |
Aug 13 2038 | 2 years to revive unintentionally abandoned end. (for year 12) |